Company intelligence / Profile preview
Aquilus Pharmaceuticals
Winchester, Massachusetts, USAaquiluspharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aquilus Pharmaceuticals has developed AQU-118—a dual MMP2/MMP9 inhibitor—as a first-in-class oral therapy targeting neurodegenerative diseases such as ALS and neuropathic pain. The compound has shown excellent safety profiles in animal models and completed all necessary preclinical studies. The company holds issued patents on composition of matter and method of use for multiple indications. Clinical trials are expected to commence soon with strong support from major grants including the NIH and ALS Association
- Therapeutic areas
- Neurology
- Modalities
- small molecules (specifically, proprietary matrix metalloproteinase [MMP] inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Funded by ALS Association Drug Development ProgramNational Institutes of Health (NIH)Department of Defense ALS Research Program; no major pharma partnerships disclosed yet
Beyond the preview
Go deeper on Aquilus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aquilus Pharmaceuticals.